Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Digital Mammography Under RSNA Spotlight As FDA Panel Meeting Nears

This article was originally published in The Gray Sheet

Executive Summary

Disagreement over interpretations of full-field digital mammography versus conventional film screen mammography images are primarily the result of differences in physician approaches to patient management, researchers from Northwestern University Medical School told attendees of the Radiological Society of North America conference Dec. 1 in Chicago.

You may also be interested in...



PMA May Be Least Burdensome Path For Digital Mammography - Feigal

Trex Medical expects to meet with FDA within the next two weeks to determine the next step in its long-sought pursuit of commercial go-ahead for its full-field digital mammography system, the company says.

Trex' Full-Field Digital Mammography 510(k) Considered Withdrawn - FDA

Trex Medical's pending 510(k) submission for its full-field digital mammography system is now considered "withdrawn" by FDA since the agency "was unable to determine substantial equivalence with analog, or 'film screen,' mammography" based on data submitted by the firm, Trex states in a Dec. 17 release.

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel